SUBSCRIBE
SUBSCRIBE

Autobahn Therapeutics

NEWS
Biotech Beach
Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B
This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.
June 9, 2020
 · 
2 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Deals
Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform
May 11, 2021
 · 
2 min read
Drug Development
Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy
April 17, 2021
 · 
3 min read
Biotech Beach
Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
 · 
1 min read
Business
Autobahn Therapeutics Strengthens its Team to Support its Continued Growth
January 5, 2021
 · 
3 min read
Business
Autobahn Therapeutics Appoints Business Leader, Scott Forrest, Ph.D., as Chief Business Officer
July 15, 2020
 · 
3 min read
Deals
Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders
June 9, 2020
 · 
4 min read
Load More